Spots Global Cancer Trial Database for esophageal cancers
Every month we try and update this database with for esophageal cancers cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | NCT03929666 | HER2-expressing... | ZW25 (Zanidatam... Capecitabine Cisplatin Fluorouracil Leucovorin Oxaliplatin Bevacizumab Gemcitabine | 18 Years - | Jazz Pharmaceuticals | |
Surgery or Chemoradiation for Esophageal Cancer | NCT01032967 | Esophageal Canc... | Esophagectomy Definitive chem... | 18 Years - 75 Years | Chinese University of Hong Kong | |
Surgery or Chemoradiation for Esophageal Cancer | NCT01032967 | Esophageal Canc... | Esophagectomy Definitive chem... | 18 Years - 75 Years | Chinese University of Hong Kong | |
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | NCT03929666 | HER2-expressing... | ZW25 (Zanidatam... Capecitabine Cisplatin Fluorouracil Leucovorin Oxaliplatin Bevacizumab Gemcitabine | 18 Years - | Jazz Pharmaceuticals | |
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers | NCT03821233 | HER2-expressing... | ZW49 | 18 Years - | Zymeworks BC Inc. | |
Surgery or Chemoradiation for Esophageal Cancer | NCT01032967 | Esophageal Canc... | Esophagectomy Definitive chem... | 18 Years - 75 Years | Chinese University of Hong Kong | |
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | NCT05152147 | Gastric Neoplas... Gastroesophagea... Esophageal Aden... | Zanidatamab Tislelizumab Trastuzumab Capecitabine Oxaliplatin Cisplatin 5-Fluorouracil | 18 Years - | Jazz Pharmaceuticals |